Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Virgínia Picanço-Castro"'
Autor:
Bárbara C.M.F. Paes, Luiza C.J.R. Stabeli, Péricles N.M. Costa, Maristela Delgado Orellana, Simone Kashima, Dimas Tadeu Covas, Virgínia Picanço-Castro
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss 2, Pp 156-164 (2021)
Introduction: Sickle cell disease (SCD) is a monogenic disease and it is estimated that 300,000 infants are born annually with it. Most treatments available are only palliative, whereas the allogeneic hematopoietic stem cell transplantation offers th
Externí odkaz:
https://doaj.org/article/6cc75d9a477c437197bd6e40b51e1ab7
Autor:
Virgínia Picanço-Castro, Pablo Diego Moço, Amanda Mizukami, Leticia Delfini Vaz, Marcelo de Souza Fernandes Pereira, Renata Nacasaki Silvestre, Júlia Teixeira Cottas de Azevedo, Aline de Sousa Bomfim, Mario Soares de Abreu Neto, Kelen Cristina Ribeiro Malmegrim, Kamilla Swiech, Dimas Tadeu Covas
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss 2, Pp 150-158 (2020)
Introduction: Adoptive transfer of T cells expressing a CD19-specific chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19 + B-cell malignancies in numerous clinical trials. The CAR molecule, which recognizes
Externí odkaz:
https://doaj.org/article/46b2df83e5f24db88e2dd8999c65cfb5
Autor:
Luciano Costa e Silva, Matheus Henrique dosSantos, Tarik Reis Heluy, Rafael Tagé Biaggio, Alexander Rodrigo Ferreira, Jonathan Milhomens, Simone Kashima, Wassim El Nemer, Sara El Hoss, Virgínia Picanço‐Castro, Dimas Tadeu Covas, Kamilla Swiech
Publikováno v:
Engineering Reports, Vol 2, Iss 6, Pp n/a-n/a (2020)
Abstract Currently, the majority of commercial recombinant therapeutic proteins are produced in nonhuman expression systems. Human cells are capable of producing recombinant proteins with post‐translational modifications that are more similar to na
Externí odkaz:
https://doaj.org/article/b8ed440e428d4c389728aa789b23ecd5
Autor:
Daianne Maciely Carvalho Fantacini, Aparecida Maria Fontes, Mário Soares de Abreu Neto, Dimas Tadeu Covas, Virgínia Picanço-Castro
Publikováno v:
Revista Brasileira de Hematologia e Hemoterapia, Vol 38, Iss 2, Pp 135-140 (2016)
ABSTRACT OBJECTIVES: The capacity of a human cell line to secrete recombinant factor VIII with a F309S point mutation was investigated, as was the effect of the addition of chemical chaperones (betaine and sodium-4-phenylbutyrate) on the secretion of
Externí odkaz:
https://doaj.org/article/1c3a0463ea7a4d30a62f41057994a95d
Autor:
Angelo Luis Caron, Virgínia Picanço-Castro, Sven Ansorge, Dimas Tadeu Covas, Amine Kamen, Kamilla Swiech
Publikováno v:
Brazilian Archives of Biology and Technology, Vol 58, Iss 6, Pp 923-928 (2015)
ABSTRACT Lentiviral vector-mediated gene transfer offers several advantages over other gene delivery vectors when considering gene and cell therapy applications. However, using these therapies in clinical applications involves large-scale vector prod
Externí odkaz:
https://doaj.org/article/c18fbe14953e4327b53dc62e57220d64
Autor:
Luiza Cunha Junqueira Reis, Virgínia Picanço-Castro, Bárbara Cristina Martins Fernandes Paes, Olívia Ambrozini Pereira, Isabela Gerdes Gyuricza, Fabiano Tófoli de Araújo, Mariana Morato-Marques, Lílian Figueiredo Moreira, Everton de Brito Oliveira Costa, Tálita Pollyanna Moreira dos Santos, Dimas Tadeu Covas, Lygia da Veiga Pereira Carramaschi, Elisa Maria de Sousa Russo
Publikováno v:
Stem Cells International, Vol 2017 (2017)
Sickle cell anemia (SCA) is a monogenic disease of high mortality, affecting millions of people worldwide. There is no broad, effective, and safe definitive treatment for SCA, so the palliative treatments are the most used. The establishment of an in
Externí odkaz:
https://doaj.org/article/9a135bf45d65432da85ef3266f38066c
Autor:
Mariane Cariati Tirapelle, Ana Luiza Oliveira Lomba, Renata Nacasaki Silvestre, Amanda Mizukami, Dimas Tadeu Covas, Virgínia Picanço-Castro, Kamilla Swiech
Publikováno v:
Cytotherapy. 24:850-860
Lentiviral vectors (LVs) have been used extensively in gene therapy protocols because of their high biosafety profile and capacity to stably express a gene of interest. Production of these vectors for the generation of chimeric antigen receptor (CAR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70e63662215d4fc3c0a0ee7e2e62bfe7
https://doi.org/10.1016/j.jcyt.2022.03.014
https://doi.org/10.1016/j.jcyt.2022.03.014
Autor:
Evandra Strazza Rodrigues, Suellen Salustiano, Elaine Vieira Santos, Svetoslav Nanev Slavov, Virgínia Picanço-Castro, Juliana Matos Maçonetto, Tissiana Marques de Haes, Osvaldo Massaiti Takayanagui, Dimas Tadeu Covas, Simone Kashima
Publikováno v:
Journal of NeuroVirology. 28:27-34
Proviral load (PVL) is one of the determining factors for the pathogenesis and clinical progression of the human T-lymphotropic virus type I (HTLV-1) infection. In the present study, we optimized a sensitive multiplex real-time PCR for the simultaneo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e3e17b960bff267958041ad0ddcaad0
https://doi.org/10.1007/s13365-020-00924-2
https://doi.org/10.1007/s13365-020-00924-2
Autor:
Martín Hernán Bonamino, Rodrigo Nalio Ramos, Vanderson Rocha, Theo G M Oliveira, Gil Cunha De Santis, Alfredo Mendrone, Virgínia Picanço-Castro
Publikováno v:
Hematology, Transfusion and Cell Therapy
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S46-S53 (2021)
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S46-S53 (2021)
Chimeric Antigen Receptor T (CAR-T) cells are certainly an important therapy for patients with relapsed and/or refractory hematologic malignancies. Currently, there are five CAR-T cell products approved by the FDA but several research groups and/or b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::485a998ecf60fc1234f2f577bb8d9613
https://doi.org/10.1016/j.htct.2021.09.007
https://doi.org/10.1016/j.htct.2021.09.007
Autor:
Virgínia Picanço-Castro, Rodrigo Nalio Ramos, Theo G M Oliveira, Martín Hernán Bonamino, Eduardo Magalhães Rego, Renato L. Guerino-Cunha
Publikováno v:
Hematology, Transfusion and Cell Therapy
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S54-S63 (2021)
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S54-S63 (2021)
Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75ec93be29168061ab60075f36834fe6
http://europepmc.org/articles/PMC8606693
http://europepmc.org/articles/PMC8606693